Utility of 21-Gene Recurrence Score for Node-Positive Breast Cancer

This week, CancerNetwork examined a review article published in the February issue of the Journal ONCOLOGY titled “Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.”

 

The piece highlights the existing literature regarding the prognostic and predictive capabilities of the 21-gene recurrence score in patients with node-positive breast cancer, focusing on current practice patterns and emerging applications from the surrounding literature.

 

For the summary, CancerNetwork spoke with 2 authors of the review, Alison Laws, MD, an associate surgeon at the Brigham and Women’s Hospital and Philip Poorvu, MD, a medical oncologist at the Dana Farber Cancer Institute. Laws and Poorvu provided valuable information on the process, focus and main takeaways of this review.

 

For the article’s response perspective, CancerNetwork spoke with Sara Hurvitz, MD, a professor of medicine at the UCLA Johnson Comprehensive Cancer Center. Hurvitz detailed a number of studies analyzed by the review article, putting into perspective the findings from various pieces of literature. She expanded on the team’s work, and looked toward the future for treating patients with node-positive breast cancer.

 
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.